T1	Participants 556 610	376 patients with newly diagnosed CML in chronic phase
T2	Participants 636 648	340 patients
T3	Participants 949 1028	534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU)
T4	Participants 1104 1135	nontransplanted living patients
T5	Participants 1246 1353	532 patients: 200 patients (38%) were low, 239 patients (45%) intermediate, and 93 patients (17%) high risk
T6	Participants 1376 1382	respon
